Treceți offline cu aplicația Player FM !
Episode: 57 - The Future of Bispecific Antibody Drug Conjugates With Rakesh Dixit, Ph. D.
Manage episode 395729987 series 2967424
Bispecific antibody drug conjugates (ADCs) have been undergoing a renaissance in recent years. As big pharma continues to express more interest, what can the field expect for the future of ADCs? In this episode of The Chain, Nimish Gera, Ph. D., Vice President of Biologics of Mythic Therapeutics, speaks with Rakesh Dixit, Ph. D., President & CEO of Bionavigen, about his thoughts on the future of bispecific ADCs, what to keep in mind when selecting targets, and how to choose the right payload. Dr. Dixit also shares his 35 years of experience with top biotech and pharmaceutical companies, including Merck, J&J, and AstraZeneca, and how he is using his expertise to advise companies with their drug development programs.
70 episoade
Manage episode 395729987 series 2967424
Bispecific antibody drug conjugates (ADCs) have been undergoing a renaissance in recent years. As big pharma continues to express more interest, what can the field expect for the future of ADCs? In this episode of The Chain, Nimish Gera, Ph. D., Vice President of Biologics of Mythic Therapeutics, speaks with Rakesh Dixit, Ph. D., President & CEO of Bionavigen, about his thoughts on the future of bispecific ADCs, what to keep in mind when selecting targets, and how to choose the right payload. Dr. Dixit also shares his 35 years of experience with top biotech and pharmaceutical companies, including Merck, J&J, and AstraZeneca, and how he is using his expertise to advise companies with their drug development programs.
70 episoade
Minden epizód
×Bun venit la Player FM!
Player FM scanează web-ul pentru podcast-uri de înaltă calitate pentru a vă putea bucura acum. Este cea mai bună aplicație pentru podcast și funcționează pe Android, iPhone și pe web. Înscrieți-vă pentru a sincroniza abonamentele pe toate dispozitivele.